Between 15 March and 6 July 2021, 348 confirmed S. Braenderup sequence type 22 (ST22) cases were reported in 12 European Union/European Economic Area (EU/EEA) countries and the United Kingdom (UK).
ECDC is supporting a large number of targeted External Quality Assessment (EQA) schemes with voluntary participation by reference or primary laboratories, which are active members of EU surveillance networks.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 May 2021 and includes updates on COVID-19, influenza, measles, Salmonella Braenderup, Ebola virus disease and cholera.
This report presents the results of the fourth round of the EQA on AST for national public health laboratories on Salmonella (hereafter Salmonella EQA4-AST) within the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net).
In 2018–2019, data on antimicrobial resistance in zoonotic and indicator bacteria, submitted by 28 EU Member States (MSs), were jointly analysed by the EFSA and the ECDC.
Between May 2018 and December 2020, 193 human cases of Salmonella Enteritidis sequence type (ST)11 were reported in Denmark (2), Finland (4), France (33), Germany (6), Ireland (12), the Netherlands (3), Poland (5), Sweden (6), and the United Kingdom (UK) (122). One in five cases was hospitalised. One death was reported. Fifty percent of the cases were children ≤ 18 years. The most recent case was reported by the UK in December 2020.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).
This report presents the results of the fourth round of the EQA on antimicrobial susceptibility testing (AST) for national public health laboratories for Campylobacter (Campylobacter EQA4-AST) within the Food‐ and Waterborne Diseases and Zoonoses Network (FWD-Net). The objectives of this EQA4-AST were to determine the accuracy of quantitative AST results reported by participants; to identify common laboratory problems related to the guidance in the EU protocol, and to assess the overall comparability of routinely collected AST data from national public health reference laboratories across Europe.